Evotec enhanced its fragment-based drug discovery business through the acquisition of certain assets from Combinature Biopharm. The company gained equipment and expertise in NMR screening and access to the SAR-by-NMR™ intellectual property, licensed from Abbott.
Evotec thus will be able to integrate NMR-based screening technologies and the SAR-by-NMR technique with its high-throughput, high-concentration biochemical assay approach. The company believes this will augment solutions for its internal pipeline as well as offerings for partnering and collaborative research.
The transaction also added a library of fragments, bringing the total up to 30,000, which Evotec states makes it the largest available fragment library from an independent fragment-based drug discovery firm.